Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate ...
Qualigen Therapeutics, Inc. (Nasdaq: QLGN Qualigen Therapeutics, Inc.), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces its financial results for the third quarter ended September 30, 2022, and provides an update on its therapeutic pipeline and other corporate developments
By Qualigen Therapeutics, Inc.
Published - Nov 15, 2022, 07:35 AM ET
Last Updated - Jun 18, 2024, 03:59 AM EDT
Q32022 FastPack ® sales increased approximately 25% year-over-year
Company continues to execute onand advance coretherapeutic programs
CARLSBAD, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN Qualigen Therapeutics, Inc.), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces its financial results for the third quarter ended September 30, 2022, and provides an update on its therapeutic pipeline and other corporate developments.
Corporate and Financial Highlights For Q3 2022 and to Date:
DiagnosticsBusiness
